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Abstract 
Mutations in the opa1 (optic atrophy 1) gene lead to Autosomal Dominant Optic Atrophy 
(ADOA), a hereditary eye disease. This gene encodes the Opa1 protein, a mitochondrial dy-
namin-related GTPase required for mitochondrial fusion and the maintenance of normal crista 
structure. The majority of opa1 mutations encode truncated forms of the protein, lacking a com-
plete GTPase domain. It is unclear whether the phenotype results from haploinsufficiency or ra-
ther a deleterious effect of truncated Opa1 protein. We studied a heterozygous Opa1 mutant 
mouse carrying a defective allele with a stop codon in the beginning of the GTPase domain at 
residue 285, a mutation that mimics human pathological mutations. Using an antibody raised 
against an N-terminal portion of Opa1, we found that the level of wild type protein was de-
creased in the mutant mice, as predicted. However, no truncated Opa1 protein was expressed. In 
embryonic fibroblasts isolated from the mutant mice, this partial loss of Opa1 caused mitochon-
drial respiratory deficiency and a selective loss of respiratory complex IV subunits. Furthermore, 
partial Opa1 deficiency resulted in a substantial resistance to endoplasmic reticulum stress-
induced death. On the other hand, the enforced expression of truncated Opa1 protein in cells con-
taining normal levels of wild type protein did not cause mitochondrial defects. Moreover, cells 
expressing the truncated Opa1 protein showed reduced Bax activation in response to apoptotic 
stimuli. Taken together, our results exclude deleterious dominant-negative or gain of function 
mechanisms for this type of Opa1 mutation and affirm haploinsufficiency as the mechanism un-
derlying mitochondrial dysfunction in ADOA. 
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Abbreviations 
ADOA, autosomal dominant optic atrophy; Opa1, optic atrophy 1; RGC, retinal ganglion cell; 
MOM, mitochondrial outer membrane; MOMP, mitochondrial outer membrane permeabiliza-
tion; WT, wild type; MEF, mouse embryonic fibroblast; COX, cytochrome c oxidase; ER, endo-
plasmic reticulum; OCR, oxygen consumption rate; Mfn1, Mitofusin 1; Mfn2, Mitofusin 2; ETC, 
electron transport chain; FCCP, 4-(trifluoromethoxy)phenylhydrazone carbonyl cyanide; STS, 
staurosporine; mtDNA, mitochondrial DNA; GFP, green fluorescent protein; Dox, doxycycline; 
DMEM, Dulbecco’s modified Eagle Medium; PBS, phosphate buffered saline; FBS, fetal bovine 
serum; SIM, structural illumination microscopy; SEM, standard error of the mean. 
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Introduction   
The optic atrophy 1 (Opa1) protein is a mitochondrial dynamin-related GTPase required for mi-
tochondrial fusion and the formation of mitochondrial cristae. These core Opa1 functions are es-
sential for mitochondrial bioenergetic competence, mitochondrial DNA stability, control of 
apoptosis, and possibly autophagy [1-10]. Additionally, recent studies demonstrate that Opa1 is 
important for the regulation of Ca2+ homeostasis [4, 11, 12]. Certain opa1 mutations lead to Au-
tosomal Dominant Optic Atrophy (ADOA), a hereditary eye disease caused by the selective loss 
of retinal ganglion cells (RGCs) and degeneration of the optic nerve. More than 200 heterozy-
gous opa1 mutations are cataloged in the current literature. These mutations are distributed along 
the entire protein coding sequence, but many are clustered in the GTPase domain (reviewed in 
[13-15]).  
Most human opa1 mutations (typically, nonsense and frame-shift) are predicted to encode trun-
cated transcripts [14-16]. Generally, transcripts with premature termination codons are prone to 
degradation via nonsense-mediated mRNA decay [17] and could therefore produce haploinsuffi-
ciency. Indeed, it has been reported that truncated transcripts often constitute less than the ex-
pected 50% of the total pool of opa1 transcripts. However, the extent of depletion of various mu-
tant opa1 transcripts in ADOA patients is highly variable, ranging from no change to an apparent 
~2/3 loss [18]. It is unclear whether truncated Opa1 proteins expressed from these shortened 
transcripts are present at all within cells, and if so, whether they have a dominant effect. A more 
severe “ADOA plus syndrome” [14, 15, 19] arises from a group of pathological point mutations 
in the GTPase domain. The affected patients exhibit multiple neuromuscular defects, in addition 
to the loss of RGCs and classical ADOA symptoms. It has been hypothesized that dominant-
negative or deleterious gain of function effects (as opposed to haploinsufficiency) account for the 
pathogenesis in these cases [14].  
Animal models for ADOA have been useful experimental systems for broader functional studies 
of Opa1 mutations. Davies and coauthors generated an Opa1 mutant mouse carrying a defective 
allele with a stop codon at residue 285 (Q285STOP) at the beginning of the GTPase domain 
[20]. This protein-truncating mutation mimics human pathological mutations in this region 
[21].[ The heterozygous Opa1Q285STOP mice have normal longevity, but gradually develop visual 
dysfunction, resembling a slow onset of the human disease. This mild ADOA-like phenotype is 
typically manifested at 6-9 months and becomes more prominent in aged animals. The delayed 
phenotype suggests that the Opa1 mutations lead to a chronic accumulation of mitochondrial 
damage, possibly in synergy with effects of aging. In contrast to this slow phenotypic onset in 
heterozygous animals, the homozygous mutant embryos are already malformed at E9.5 and die 
before E14.5 [20]. Early embryonic lethality is also observed in homozygotes from other mouse 
ADOA models [22, 23].  
In the heterozygous Opa1Q285STOP mice, mutant and normal transcripts are present at the same lev-
el. As expected, full-length (WT) Opa1 protein is reduced by ~ 50% in most tissues tested, but it 
is not known whether truncated mutant polypeptides are produced [20, 21]. In Opa1Q285STOP car-
diomyocytes, age-dependent reductions in the activities of electron transport chain (ETC) Com-
plexes I and IV were observed, possibly linked to mtDNA instability [24]. However, in skeletal 
muscle, no changes in mtDNA levels and Complex IV activity were detected [25], implying that 
the mitochondrial defects are tissue-specific. 
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Major loss of Opa1 function (e.g. in cells treated with opa1 siRNA) typically sensitizes cells to 
mitochondrial apoptosis [2-4], whereas Opa1 overexpression has a moderate protective effect [8, 
9, 26]. Opa1 complexes have a role in keeping mitochondrial crista junctions in a closed state, 
limiting cytochrome c mobilization from the crista interior. Thus, it is important for apoptotic 
cells to disassemble Opa1 complexes, to allow complete release of soluble proteins from the cris-
tae during apoptosis [8, 9]. Indeed, we showed that the overexpression of a mutant Opa1 with 
enhanced self-assembly strongly reduces Bax/Bak-induced cytochrome c release into the cytosol 
[8]. This inhibition of Opa1 disassembly does not affect Bax translocation and activation in the 
mitochondrial outer membrane (MOM), which occur upstream and independently of crista re-
modeling events [8, 9]. A recent study showed that the disassembly of Opa1 complexes and cy-
tochrome c release require proteolytic cleavage of Opa1 by the mitochondrial metalloprotease 
Oma1 [27].  
It is also conceivable that reduced Opa1 function could sensitize cells to apoptosis and other 
forms of cell death indirectly, by compromising ATP levels and overall mitochondrial bioener-
getic integrity. With regard to ADOA, it remains unclear whether Opa1 mutations promote the 
disease through effects on apoptosis. Some studies found no evidence for increased apoptotic 
death in human cells harboring ADOA-linked mutations [28, 29]. In RGCs, decreased Opa1 
function was also associated with autophagic [7, 30] and excitotoxic [4, 31] cell death pathways. 
In both cases, cell death is caused at least partly by mitochondrial bioenergetic defects.  
Here we investigated the pathological mechanism underlying mitochondrial dysfunction in the 
Opa1Q285STOP ADOA mice. When we examined MEFs from these animals, we found a bioenerget-
ic deficiency, as well as decreased expression of components of cytochrome oxidase (COX) con-
sistent with reduced enzymatic COX activity.  The respiratory deficiency increased as the cells 
were passaged, Further, we found that the predicted Opa1 truncation mutant protein was unde-
tectable in MEFs and tissues from the animals. This implies that haploinsufficiency, rather than a 
dominant-negative effect of truncated Opa1 protein, is the primary mechanism for the ADOA-
like phenotype. We therefore suggest that the human disease may also result from Opa1 haploin-
sufficiency. Interestingly, we found that Opa1Q285STOP MEFs are relatively resistant to apoptosis 
induced by endoplasmic reticulum (ER) stressors, while showing increased or normal sensitivity 
to other apoptotic stimuli. This suggests a novel functional link between Opa1 and ER stress-
induced mitochondria-dependent cell death. To compare the phenotypic effects of Opa1 haploin-
sufficiency versus concurrent expression of truncated and WT protein, we enforced the expres-
sion of truncation mutants in cultured cells. We found that mitochondrial respiration was not im-
paired, again suggesting that mitochondrial functional defects arise from the lack of sufficient 
Opa1 function rather than a dominant negative effect of truncated protein.  Surprisingly, the ex-
pression of mitochondria-targeted truncated Opa1 mutants inhibited apoptotic Bax activation. 
This suggests that the N-terminal portion of WT Opa1 could be involved in apoptotic signaling 
from the inner mitochondrial membrane outward to the mitochondrial outer membrane (MOM) 
or cytoplasm.  
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Results and Discussion 
Bioenergetic function is impaired in late-passage Opa1 mutant mouse embryo fibroblasts. 
Opa1Q285STOP mice have been characterized in terms of visual dysfunction, neuromuscular defects, 
optic nerve atrophy, and RGC abnormalities [20, 21]. However, published data on mitochondrial 
function in this ADOA model are inconclusive. In one study, estimation of the membrane poten-
tial in isolated brain and retinal mitochondria (using JC-1 dye) showed no changes in the mutant 
samples, even though the authors observed abnormal mitochondrial ultrastructure with reduced 
numbers of cristae [32]. In contrast, a significant decrease in respiratory function was reported 
for isolated heart mitochondria [24].  To analyze consequences of the Q285STOP mutation, we 
isolated MEFs from heterozygous animals. We first confirmed the predicted ~50% loss of full-
length (WT) Opa1 protein by immunoblots (Fig. 1A and Fig. 3). The levels of long and short 
Opa1 isoforms were reduced to a similar extent, indicating that Opa1 processing was not affected 
(Fig. 1A).  
In individual WT and mutant cells, mitochondrial network morphologies fell into three catego-
ries: heterogeneous, mostly elongated (fused), or mostly fragmented (Fig. 1B,C). Quantification 
of the different phenotypes showed that on average, mitochondria were more fragmented in the 
heterozygous Opa1Q285STOP mutant cells than in WT (Fig. 1D). This is consistent with a partial 
loss of Opa1-dependent mitochondrial fusion. However, a significant fraction of mutant cells 
contained elongated mitochondria, which suggests that even halved levels of WT Opa1 can sup-
port mitochondrial fusion substantially. Total mitochondrial mass in these cells was likely pre-
served, as we detected normal levels of the matrix marker Hsp60 and membrane markers Tom20 
and VDAC (Fig. 2E). 
Superficially, the loss of 50% of Opa1 protein appeared not to affect cell function, as WT and 
Opa1 mutant MEFs displayed similar growth patterns that are typical for primary MEF cultures 
[33]: after initial rapid proliferation, cell division started to decline after 4-5 passages and virtual-
ly stopped after 8-10 passages. Moreover, in early passage cells, no bioenergetic changes were 
detected. However, in mutant cells at later passages, we observed decreased mitochondrial mem-
brane potential (Fig. 2 A,B) and oxygen consumption rates (OCR), compared with WT (Fig. 
2C,D). Oligomycin-inhibited OCR (state 4), an indicator of proton leak through the inner mem-
brane, was not elevated in mutant cells (Fig. 2C,D). Also, the rates of ADP-induced (state 3) res-
piration measured in situ in cells with selectively permeabilized plasma membrane (to allow the 
access of exogenously added ADP to mitochondria) were reduced in Opa1 mutant cells (Fig. 
S1A). This demonstrates that the decrease in the membrane potential was caused by partial res-
piratory inhibition and not by mitochondrial uncoupling.  
The bioenergetic defect can be explained by a functional deficiency of Complex IV (Cytochrome 
c oxidase [COX]), as the levels of the mitochondrial-encoded subunits COX I and COX II, but 
not nuclear-encoded COX Va subunit, were lower in Opa1 mutant MEFs than in control cells 
(Fig 2E and Fig.S1B). Furthermore, Opa1 mutant MEFs showed significantly reduced enzymatic 
activity of Complex IV, assayed as oxidation of its artificial specific electron donor TMPD 
(N,N,N’,N’-tetramethyl-p-phenylene diamine) by measuring oxygen consumption rate (Fig. 
2F,G). Our observations of reduced COX protein levels and activity in Opa1Q285STOP MEFs are 
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consistent with published functional and histological evidence for COX deficiency in cells with 
various Opa1 mutations [28, 34].  
Because levels of mitochondrial-, but not nuclear-encoded Complex IV protein levels were re-
duced in Opa1 mutant MEFS, our results raise the possibility that could Opa1 haploinsufficiency 
leads to a partial loss of mtDNA. Further study will be needed to determine levels of mtDNA. 
However, arguing against this potential mechanism are reports in the literature; for example, a 
study of skin fibroblasts from ADOA patients reported decreased COX enzymatic activity in the 
absence of detectable changes in the amount of mtDNA [28]. Similarly, a mtDNA-independent 
decrease in COX (but not Complex I) activity was observed in mice lacking Opa1 in pancreatic 
beta cells [35]. In cells with a more profound loss of Opa1, we saw an even more severe respira-
tory deficiency.  Immortalized opa1-null MEFs [6] showed a nearly complete loss of mitochon-
drial respiration, major depletion of both mitochondrial and nuclear-encoded ETC components, 
and a significant decrease in the level of Tom20 (Fig. 2E and Fig. S1B). This also suggests that a 
loss of mtDNA by itself is unlikely to account for the observed mitochondrial dysfunction. 
Recent studies highlighted a role of Opa1-dependent crista integrity in the assembly of individual 
ETC complexes into higher order supercomplexes (e.g., Complex I-III, Complex I-III-IV, and 
Complex III-IV) that may enhance ATP production [36]. In particular, acute short-term Opa1 
ablation preserved mtDNA levels and translation of mitochondrially-encoded subunits but, nev-
ertheless, led to compromised mitochondrial bioenergetic efficiency, which correlated with defi-
cient assembly of ETC supercomplexes [5].  It was not entirely clear to what degree this defect 
affected total levels of individual active respiratory complexes. Further study will be needed to 
determine whether Opa1 haploinsufficiency affects the assembly of respiratory supercomplexes 
in cells from Opa1Q285STOP mice.  
Ordinarily, COX is expressed at levels conferring significant functional excess compared to oth-
er electron transport chain complexes, which may explain the typically subtle or absent respirato-
ry defects in cells with heterozygous Opa1 mutations. However, an earlier bioenergetic study 
argued that the functional excess of COX activity in whole cells (as opposed to isolated mito-
chondria) does not exceed 20-40% [37]. The threshold level of COX required for normal respira-
tion may be variable between cell types and affected by oxygen and substrate availability, cyto-
chrome c pools, and ATP demand [37, 38]. Thus, the ~40% COX reduction seen in late passage 
Opa1Q285STOP MEFs might cause COX to become rate-limiting for electron transport chain func-
tion. One can also hypothesize that in RGCs and other relevant cells, a lower spare respiratory 
capacity of COX or other ETC components (rather than protein level per se) makes them more 
vulnerable to pathogenic Opa1 mutations.  
The truncated form of Opa1 is not expressed in the Opa1Q285STOP mouse  
It is still not fully understood whether the genetic dominance of ADOA results from haploinsuf-
ficiency or a dominant effect of the mutant protein. As noted above, in the Opa1Q285STOP mouse, 
mutated Opa1 transcript is not degraded [20]. We considered the possibility that the N-terminal 
Opa1 fragment is expressed and active in some way. To test this, we analyzed MEFs and tissues 
from the Opa1 mutant mice by immunoblot, using an affinity-purified antiserum raised against a 
recombinant Opa1114-289 polypeptide, which recognizes the truncated forms of Opa1. Also, we 
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generated HeLa cell lines with doxycycline-inducible expression of a nearly identical FLAG-
tagged Opa1 truncation mutant (Opa11-289; Fig. 5A).  
Whereas inducibly expressed Opa11-289 protein in cultured cells was readily detected by our anti-
body, endogenous Opa11-285 protein was not detected in any of the samples (including liver mito-
chondria) derived from the mutant mice (Fig. 3A,C). As expected, the level of WT Opa1 in mu-
tant mice was reduced by nearly half in all tissues tested (Fig. 3B). Because the predicted trun-
cated Opa1 mutant protein was undetectable, we conclude that the bioenergetic defects (Fig. 2) 
and other previously described abnormalities in the Opa1Q285STOP mouse [21] arise purely from 
haploinsufficiency of WT Opa1. A prior study of another mouse ADOA model with a different 
mutation (Opa1329-355del) similarly detected no shortened Opa1 mutant proteins in various tissues 
tested [22]. The mechanisms underlying this absence of truncated Opa1 products in ADOA mu-
tant mice are unknown. Degradation of truncated Opa1 by canonical proteasomes is probably not 
involved, as we found that pretreatment of mutant MEFs with MG132, a proteasome inhibitor, 
did not cause the mutant protein to appear (Fig. 3D). 
Effect of the Opa1 mutation on apoptosis depends on the type of apoptogen  
Experimental silencing of Opa1 typically increases cellular sensitivity to various apoptotic 
stimuli [2, 4, 39, 40]. Increased susceptibility of opa1-heterozygous fibroblasts from ADOA pa-
tients to cell death has been also reported [39, 41]. However, changes in apoptotic response are 
often absent or less pronounced in ADOA cells [28, 29]. Previous studies of retinal and cardiac 
tissues from the Opa1Q285STOP mutant mouse found no evidence for increased basal frequencies of 
apoptosis [21, 24], but the effects of agents that stimulate apoptosis (apoptogens) have not been 
tested in this ADOA model. We compared the responses of WT and Opa1Q285STOP MEFs to vari-
ous apoptotic stimuli. To prevent rapid deterioration and loss of cells as a result of caspase acti-
vation, all apoptogens were added in the presence of a caspase inhibitor (Q-VD). Since mito-
chondrial function is ultimately compromised in cells that have undergone mitochondrial outer 
membrane permeabilization (MOMP), even when caspase activity is blocked [42], we used mi-
tochondrial respiration as a measure of the viability and bioenergetic competence of apoptogen-
treated cells. As expected, all of the drugs caused a significant decline in maximal respiratory 
capacity (state 3u or uncoupler-stimulated OCR) in both WT and mutant cells (Fig. 4A,B). There 
were no significant differences between WT and Opa1Q285STOP MEFs in their responses to etopo-
side or actinomycin D. Thus, a 50% reduction in the Opa1 level did not sensitize cells to death in 
response to some apoptogens. However, the mutant cells were slightly more sensitive to stauro-
sporine (STS).  
Unexpectedly, we found that Opa1 mutant MEFs were more resistant than WT to two inducers 
of ER stress, tunicamycin and thapsigargin (Fig. 4 A-D). A 24-h treatment with these agents led 
to a decline in respiration in WT MEFs, but this effect was blunted in the heterozygous 
Opa1Q285STOP MEFs (Fig. 4 A,B). Cell death in response to ER stress typically involves Bax/Bak-
dependent MOMP [43, 44]. To confirm that the observed decline in respiration reflected the oc-
currence of Bax-dependent apoptosis, we used immunofluorescence microscopy to quantify the 
percentage of cells stained with antibodies (N20 or 6A7) recognizing activated Bax. Mitochon-
drial localization of activated Bax was confirmed by co-staining with antibodies to Tim23. 
Apoptotic cells displayed the typical clusters of activated Bax at mitochondria (Fig. 4E). Essen-
tially all cells with activated Bax underwent MOMP, as demonstrated by a loss of cytochrome c 
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immunostaining (shown for etoposide-treated cells in Fig. 4E). In the absence of apoptogens, few 
cells showed mitochondrial Bax(N20) staining. Overall, results from immunostaining experi-
ments were consistent with the data in Fig. 4B. Thapsigargin and tunicamycin treatment pro-
duced less apoptosis in Opa1 mutant MEFs than in WT, while the effects of etoposide were simi-
lar in WT and Opa1 mutant MEFs (Fig. 4F,G). Furthermore, image analysis confirmed increased 
sensitivity of Opa1 mutant MEFs to STS treatment (Fig. 4F).  
ER stress typically leads both to a rapid Ca2+ pulse released from the ER and to a slower tran-
scriptional response (reviewed in [45]). Although tunicamycin (an inhibitor of N-glycosylation) 
and thapsigargin (an inhibitor of ER/sarcoplasmic Ca2+ pumps) target different ER functions, 
both of them induce similar sustained mitochondrial Ca2+ increases within several minutes [46]. 
It is conceivable that early energy-dependent mitochondrial Ca2+ uptake is compromised in Opa1 
mutant MEFs, as has been demonstrated in other Opa1-deficient cells [4]. Other recent studies 
have shown that the mitochondrial outer membrane fusion proteins Mfn1 and Mfn2 can also 
modulate the cellular response to ER stress. One proposed mechanism involves interaction of 
Mfn2 with PERK, the ER-resident protein kinase initiating signaling events comprising specific 
ER stress response [47]. Another mechanism involves a more general effect in which very small 
mitochondria are relatively resistant to Bax-mediated MOMP [44]. In both cases, loss of Mfn1 or 
Mfn2 function reduced ER stress-mediated apoptosis. Further study will be required to elucidate 
the mechanisms through which Opa1 haploinsufficiency leads to resistance to ER stress-induced 
apoptosis.  
Overexpression of Opa11-289 had no effect on mitochondrial morphology and respiration 
but decreased Bax activation 
As shown above, the mutant Opa11-285 polypeptide was not detected in vivo (Fig 3). While the 
repression mechanism for the truncated protein is unknown, we asked whether a similar truncat-
ed Opa1 protein, if expressed, could cause defects in mitochondrial morphology or respiration. 
We used HeLa cells to generate a cell line with stable doxycycline-inducible expression of 
FLAG-tagged Opa11-289 (Fig. 5A). (The breakpoint at residue 289 had been chosen for an earlier 
study, but is very close to the predicted protein truncated at residue 285 in the mutant mice; both 
would lack the dynamin-like GTP binding domain but retain the coiled-coil domain). For com-
parison, we tested two other mitochondria-targeted mutants (Opa11-195 and Opa11-468; Fig. 5A) in 
some experiments.   
We found that the inducible Opa11-289 protein was localized in mitochondria, as shown both by 
confocal immunofluorescence microscopy (Fig. 5C) and by subcellular fractionation (Fig 5B). 
Immunostaining with our Opa1 antibody recognizing both WT and the mutant Opa1 showed that 
the level of Opa11-289 overexpression did not exceed 2 fold (vs. endogenous normal Opa1) in 
most cells (Fig. 6A). Despite the modest overexpression levels, Opa11-289 -expressing cells appar-
ently had a selective disadvantage, as we observed these cells being rapidly outgrown by a sub-
population of non-expressing cells (Fig. 6A).  
To localize the Opa1 mutant, we used immunofluorescence microscopy. Surprisingly, the mutant 
Opa1 was distributed in small clusters associated with mitochondria, whereas endogenous Opa1 
was distributed more uniformly throughout mitochondria (Fig. 5C and Fig. S2). Fig. 5 (C,D) 
shows that Opa11-289 expression did not affect mitochondrial elongation/fragmentation, as we 
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observed that this protein was present in fused (tubular or elongated) mitochondria of normal 
lengths (typical for HeLa cells). Similarly, expression of the shorter (1-195) and longer (1-468) 
N-terminal truncated mutants did not alter mitochondrial morphology. In contrast, overexpres-
sion of WT Opa1 resulted in mitochondrial fragmentation (Fig. 5C,D), as has been observed in 
other studies [6, 48].  
To analyze the submitochondrial localization of the truncated Opa1 mutant protein, we used 
structural illumination microscopy (SIM). Image analysis (Fig. S2) displays the three-
dimensional distance from fluorescent Opa1 speckles (either the mutant or WT) to the center of 
neighboring fluorescent speckles in Tim23-labeled mitochondria. The distance between the inner 
membrane marker Tim23 and Opa11-289 was similar to that determined for Tim23 vs. endogenous 
WT Opa1, which is known to be localized in the inner membrane [48]. Also, Opa11-289 was more 
proximal to Tim23 than to the outer membrane marker Tom20 as determined by comparison 
with Tom20 labeled mitochondria (Fig. S2). Additionally, the relative distance between Tom20 
and Opa11-289 was very similar to that determined for Tom20 vs. Tim23 (Fig. S2). Taken togeth-
er, the data indicate that Opa11-289 is localized in the MIM, as expected.  
Next, we tested whether Opa11-289 had an effect on mitochondrial respiration in the doxycycline-
induced cells. Although Opa11-289 expression was typically unstable even at low expression lev-
els, we were able to isolate clones maintaining Opa11-289 expression in ~70-80% cells (as deter-
mined by FLAG immunostaining) for up to two days after doxycycline addition. We used these 
cells (derived from four individual clones) for bulk measurements of oxygen consumption in in-
tact cells. Unlike the Opa1-haploinsufficient MEFs, Opa11-289-expressing HeLa cells (which con-
tain normal levels of endogenous WT Opa1), showed no decrease in mitochondrial respiration 
(Fig 5E). Furthermore, mitochondria containing the Opa1 mutants exhibited unaltered staining 
by the membrane potential-sensitive dye TMRE (not shown). Thus, we found no obvious effects 
of the Opa1 truncation mutants on mitochondrial morphology and function.  
Finally, we asked whether Opa11-289 expression altered the susceptibility of cells to apoptosis. 
Western blot analysis of whole cell lysates showed that induction of apoptosis by certain agents 
caused a degradation of both mutant and normal Opa1 (Fig. S3). Because apoptotic cells lose at 
least some of their Opa1 content, we could not determine by simple immunostaining whether 
apoptotic cells had expressed FLAG-tagged Opa1 prior to mitochondrial permeabilization. 
Therefore, to quantify the effects of mutant Opa1 expression on apoptosis in heterogeneous cell 
populations containing both expressing and non-expressing cells, we used an IRES-containing 
bicistronic vector to express both the FLAG-tagged Opa1 mutant and GFP, as a marker. Fig. 6A 
confirms that Opa11-289-expressing cells were both GFP- and FLAG-positive, while cells lacking 
the mutant were largely GFP-negative. Also, as expected, mitochondria in cells with higher GFP 
expression displayed a higher signal from immunostaining with the N-terminal Opa1 antibody 
(Fig. 6A, bottom panels). After treatment of the cells with etoposide, we determined the percent-
age of apoptosis among GFP-positive and GFP-negative cells by Bax immunostaining and con-
focal microscopy. Quite unexpectedly, we found that Opa11-289-expressing cells showed less Bax 
activation than non-expressing (GFP-negative) or vector control cells (Fig. 6B,C). We also ob-
served increased resistance to etoposide-induced apoptosis in cells expressing the longer mutant 
Opa11-489 (not shown), but not the shorter polypeptide Opa11-195 lacking the coiled-coil domain 
(Fig. 6B,C).   
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Previous reports have demonstrated that Opa1 plays a role in apoptosis by controlling a mito-
chondrial inner membrane-remodeling step (crista junction opening) necessary for the release of 
mitochondrial proteins from cristae [8, 9]. We showed that this Opa1-dependent crista junction 
remodeling is Bax/Bak-dependent, downstream of Bax activation, and independent of MOMP 
[8]. In contrast to that event, in which Bax and Bak activation signals inward to Opa1, here we 
describe a different situation in which an N-terminal fragment of Opa1 can signal outward to in-
hibit MOM permeabilization, possibly by interacting with another mitochondrial protein. As the 
N-terminal membrane-integration domain is required for this effect (not shown), we considered 
Higd1a, an inner membrane protein interacting with the N-terminal portion of Opa1, as a candi-
date [49]. However, we found that siRNA silencing of that protein had no effect on etoposide-
induced apoptosis (not shown). It remains to be investigated how the signal from native Opa1 (or 
its mutant forms) in the inner membrane is conveyed to the MOM or upstream of MOMP.  
Thus, the overexpression of mitochondria-targeted Opa1 truncation mutants causes no obvious 
deleterious effects such as mitochondrial dysfunction or increased cell death. In any case, our 
data rule out the expression of a truncated Opa1 mutant in the Opa1Q285STOP mouse ADOA model, 
allowing us to conclude that the ADOA-like phenotype results entirely from haploinsufficiency. 
This suggests that similar Opa1-truncating mutations in humans may also arise from Opa1 hap-
loinsufficiency, rather than a dominant effect of mutant Opa1 protein. As we showed, haploin-
sufficiency in the mice results in defects in mitochondrial respiration and COX expression. We 
propose that these defects could lead to metabolic stress in certain vulnerable cell types such as 
RGCs or cardiac muscle.  
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METHODS   
Animals and mouse embryonic fibroblast preparation 
Heterozygous Opa1Q285STOP mice (on the C57Bl/6 background) were generated previously [20]. 
Mouse colony maintenance and all animal work were approved by the Institute’s Animal Care 
and Use Committee. Genotyping was performed at Transnetyx (Cordova, TN). Primary cultures 
of mouse embryonic fibroblasts (MEFs) were generated as described [33]. Briefly, embryos were 
collected in individual dishes from E13.5-E15.5 Opa1Q285STOP mice, dissected and incubated in 
0.25% trypsin-EDTA solution at 4 °C overnight. The next day the tissue was dissociated and cell 
suspension obtained from each embryo was plated in 5-6 10-cm dishes with DMEM medium 
(Life Technologies) containing penicillin and streptomycin (100 units/ml and 1000 µg/ml, re-
spectively) and 10% fetal bovine serum (FBS) and (Gemini Bio-products). Opa1 mutant and the 
littermate control (WT) MEFs were expanded during the rapid proliferation at early passages and 
maintained in the culture up to 10-15 passages. Immortalized opa1-null and control MEFs were 
obtained from ATCC. 
Production of antibody against N-terminal portion of Opa1 (114-289) 
Truncated Opa1(114-289) in pET28 (no FLAG-tag) was expressed in BL21(DE3) cells. The pro-
tein was solubilized from the inclusion bodies in 8M urea, purified with Ni++-NTA agarose (Qi-
agen) and used to immunize rabbits. Opa1 antiserum was produced using a 13-week antibody 
production protocol at Pacific Immunology (Ramona, CA). Specific immunoglobulin for 
Opa1(114-289) was affinity-purified using recombinant Opa1(114-289) protein coupled to Se-
pharose as follows. Bacterially expressed Opa1(114-289) was solubilized in PBS containing 1% 
Triton X-100 and purified on Ni++-NTA agarose. The protein (2.7 mg) was coupled to 1.35 ml 
CNBr-Sepharose (GE) according to the manufacturer’s instructions. Ten ml of the antisera from 
later bleeds were incubated with the truncated Opa1 coupled Sepharose overnight at 4oC. The 
beads were washed and eluted with 0.1M Glycine-HCl, pH 3.0, 0.5M NaCl and the eluted frac-
tions were immediately neutralized with 1M Tris, pH 8. The peak immunoglobulin fractions 
were collected, dialyzed in PBS and concentrated to 0.85 mg/ml.  
Western Blot Analysis 
For analysis of Opa1 protein in different tissues, samples of retina, brain, spleen and liver were 
collected from aged (>12 month old) Opa1 mutant and littermate WT animals. Livers were used 
for isolation of mitochondria by differential centrifugation [50]. In some experiments, tissue 
samples and liver mitochondria were isolated from younger (3 month old) mice. For immunob-
lotting, tissue lysates or isolated mitochondria were loaded on NuPage 4%-12% Bis-Tris gels 
(Life Technologies) at 30-50 µg per lane. For western blot analysis of Opa1 and other proteins in 
cultured cells, cell aliquots (~0.5-1 million) were centrifuged at a low speed and the pellets were 
resuspended in 50-100 µl ice-cold lysis buffer containing 0.5% Nonidet P-40, 50 mM Tris-HCl 
(pH 8.0), 150 mM NaCl, and 1X Complete protease inhibitor mixture (Roche). After 20 min in-
cubation on ice, whole cell lysates were centrifuged at 15,000x g for 15 min. Supernatants were 
used for the analysis. For subcellular fractionation, cells inducibly expressing Opa1 mutant or 
vector control were permeabilized with digitonin (0.008% per 3 millions cells) in 0.5 ml buffer 
containing 125 mM KCl, 2 mM KH2PO4, and 20 mM HEPES-KOH (pH 7.4). Cytosolic and 
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membrane (mitochondria-enriched) fractions were separated by centrifugation at 15,000 x g for 3 
min at 4 °C.  Whole cell extracts or subcellular fractions were loaded on the gels at 30-40 µg per 
lane. Protein concentrations were determined by Pierce BCA protein assay (Thermo Scientific). 
Gels were run at 200 V for 45 min. Proteins were electrotransferred to nitrocellulose membrane 
(BioRad) at 30 V for 75 min. The membranes were blocked in 2.5% milk overnight at 4 °C and 
probed with the custom-made rabbit Opa1 antisera. Other antibodies used were: VDAC (porin) 
(anti-mouse from Calbiochem; anti-rabbit from Abcam), cytochrome c (BD-PharmingenTM, BD-
Biosciences), cytochrome c oxidase (COX) subunits I and II (Molecular Probes) and COX Vb 
(Abcam), Hsp60 (Santa Cruz Biotechnology), NDUFB8 (Novex, Life Technologies), NDUFS7 
(20 kDa subunit) (Molecular Probes), Drp1(Dnm1) (BD Transduction Laboratories), Tom20 
(Santa Cruz Biotechnology), and Bax(N20) (Santa Cruz Biotechnology). A mouse Opa1 anti-
body (BD Transduction laboratories) was used for the immunoblot shown in Fig.1A. Anti-
FLAG(M2) antibody was from Sigma.  Secondary antibodies used were horseradish peroxidase-
conjugated anti-mouse and anti-rabbit antibodies (Amersham), or an anti-goat antibody (Santa 
Cruz Biotechnology). Protein bands were detected using either SuperSignal WestPico or Super-
Signal West Femto reagent (Thermo Scientific) and X-ray film. 
Generation of Tet-on inducible HeLa cells 
We used a Tet-on gene expression system to induce expression of indicated Opa1 mutant pro-
teins (Fig. 5A). Each mutant or wild type Opa1 was PCR-amplified and inserted at the multiple 
cloning site of pTRE2hyg (Clontech) that contained a tetracycline-responsive promoter. We also 
constructed pTRE2hyg-OpaI with IRES-GFP, in order to monitor the induction of the protein. 
PCR-amplified IRES-GFP was inserted downstream of Opa1. All the constructs were verified by 
sequencing. The cells were transfected with lipofectamine 2000 (Life Technologies) and stably 
expressing cells were selected in the presence of G418 (200-400 µg/ml) and hygromycin B (200-
400 µg/ml) (Gemini Bio-products). Opa11-289-IRES-GFP cells were sorted to enrich the popula-
tion with the Opa11-289-expressing (GFP-positive) cells. Cells were maintained in DMEM medi-
um containing 10% Tet system approved FBS (Clontech), 100 µg/ml G418 and hygromycin B. 
The medium was changed every 3-4 days. Experiments were performed 1-2 days after induction 
with doxycycline (5 µg/ml).   
Immunostaining, confocal and superresolution microscopy 
For fluorescent microscopy, cells were grown on 35 mm glass bottom MatTek dishes (MatTek 
corporation) or glass coverslips #1.5 (Corning) placed in 6-well plates. Cells were fixed with 
0.5% glutaraldehyde diluted in PBS from an 8% stock solution (Sigma) for 40 min at 4 °C. Auto-
fluorescence was quenched by 0.5% freshly prepared sodium borohydride for 30 min at room 
temperature for 30 min. Cells were permeabilized with 0.5% Triton X-100 in PBS (15 min), fol-
lowed by 1 hour incubation in blocking buffer containing 2% bovine serum albumin, 0.05% 
Tween-20, and 0.1% NaN3 in PBS prior to the addition of primary antibodies. The antibodies 
used were: Bax(N-20) and Tom20 (FL-145) from Santa Cruz Biotechnology, Inc.; mouse cyto-
chrome c  (BD PharmingenTM), Tim23 (BD Biosciences), Bax (6A7) (TACSTM ), FLAG(M2) 
from Sigma or Alexa 647-conjugated FLAG (Cell Signaling). The antibodies were diluted at 
1:500 in the blocking buffer; Tom20 antibody dilution was 1:1000. Samples were incubated with 
primary antibodies for 1-2 h at RT, washed several times with PBS and incubated in the blocking 
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buffer for 30 min before the addition of secondary fluorophore-conjugated antibodies (usually, 
diluted 1:500 in the blocking buffer) for 1.5-2 h at RT. The secondary antibodies used were: rab-
bit or mouse Alexa-488, Alexa-568 and Alexa-647 (Life Technologies). Nuclei were stained 
with Hoechst 33342 (1:10000 dilution) and washed in PBS. Samples prepared for superresolu-
tion microscopy (below) were additionally post-fixed in 4% paraformaldehyde in PBS. Stacks of 
confocal images were acquired with a 60x (1.3na) oil immersion objective on an Olympus 
FluoView FV10i automated confocal laser-scanning microscope. Images reconstructed in 3D 
(Fig. 5C, panels a-d) were generated on a Nikon A1R confocal super-resolution system (using a 
100x (1.46na) oil immersion objective. Stacks of z-series images were collected using a 0.1 µm z 
step size. Images were then further rendered and processed in the IMARIS 3D modeling soft-
ware (Bitplane-Andor Inc.). 
In imaging experiments involving quantification of cells with different phenotypes, 100-300 cells 
in each experiment (n ≥ 3) were blindly counted for each sample. The percentage of cells with 
activated Bax was determined based on Bax(N20) antibody staining. In some experiments, cells 
were co-stained with cytochrome c antibody to confirm that cytochrome c was released from mi-
tochondria in apoptotic cells (i.e. cells with activated Bax). The concentrations of apoptogens are 
indicated in figure legends. All apoptogens were added in the presence of caspase inhibitor Q-
VD (Q-VD-OPH, SM Biochemicals LLC). In the absence of added apoptogens, the number of 
cells showing Bax(N20) staining was negligibly small. Quantification of the cells with different 
mitochondrial morphologies (e.g., tubular or fragmented) was based on immunostaining with 
mitochondrial markers (cytochrome c, Tom20 or Tim23). 
Superresolution microscopy. Images were also acquired using either a Zeiss Structural Illumina-
tion microscopy (SIM) ELYRA S13D Superresolution Microscope or a Zeiss 880 laser scanning 
confocal microscope with Airy Scan super resolution. Z series image stacks of multilabeled sam-
ples immunostained for Tom20, Tim23, and Opa1 were optically acquired with a 63x (1.4na) 
objective using a 0.10µm step size and then processed using ZEN software (Zeiss Inc.). Further 
processing and rendering of images was completed using the IMARIS software (Bitplane-Andor 
Inc.). In IMARIS, fluorescent signals were iso-surfaced into 3D objects in order to create dis-
tance transform maps (MATLAB macro) of the objects defining their spatial relationship to each 
other. Once the objects were defined, Opa1-positive 3D signal objects were compared to either 
Tom20 or Tim23 labeled 3D objects, and the final distance transform image displayed is shown 
as a color coded distance map: green-red - less than 140nm; purple blue -greater than 140nm (see 
Fig. S2). Additionally, the distance map was generated for Tim23 vs. Tom20 for comparison 
(Fig S2, bottom panels). Counts shown in the figures represent an averaged percentage +/-SEM 
of the total number of objects per cell that are grouped as the shortest distance between objects. 
An average of 3 cells per group was analyzed. 
In imaging experiments involving quantification of cells with different phenotypes, 100-300 cells 
in each experiment (n ≥ 3) were blindly counted for each sample. The percentage of cells with 
activated Bax was determined based on Bax(N20) antibody staining. In some experiments, cells 
were co-stained with cytochrome c antibody to confirm that cytochrome c was released from mi-
tochondria in apoptotic cells (i.e. cells with activated Bax). The concentrations of apoptogens are 
indicated in figure legends. All apoptogens were added in the presence of caspase inhibitor Q-
VD (Q-VD-OPH, SM Biochemicals LLC). In the absence of added apoptogens, the number of 
cells showing Bax(N20) staining was negligibly small. Quantification of the cells with different 
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mitochondrial morphologies (e.g., tubular or fragmented) was based on immunostaining with 
mitochondrial markers (cytochrome c, Tom20 or Tim23). 
Respiration (oxygen consumption) measurements and flow cytometry.  
Respiration of intact MEFs was measured with Seahorse Bioscience XF24, XF96 or XFe96 Flux 
Analyzers. Cells were plated on the Seahorse cell culture plates in their growth medium at a den-
sity of 2 ×104 or 104 cells per well for 24- and 96-well plates, respectively for 24 hours before the 
measurement.  For apoptogen testing, cells were plated 48 h prior to the experiment at a density 
of 104 or 5 ×103 cells per well for 24- and 96-well plates, respectively. At times indicated in the 
Figure legends, the medium was supplemented with an equal volume of the same medium con-
taining 2X concentrations of various apoptogens. Immediately before measurement the medium 
was removed, and the cells were gently washed with assay buffer (unbuffered DMEM prepared 
according to Seahorse protocols and supplemented with 10 mM glucose, 10 mM sodium py-
ruvate and 1X GlutaMax, pH 7.4). Wells were filled with 450 or 100 μl of assay buffer for 24- 
and 96-well plates, respectively, and the measurements were performed in the Seahorse appa-
ratus according to manufacturer’s recommendations. Enzymatic activity of mitochondrial Com-
plex IV was measured in cells permeabilized with 3 nM perfringolysin O (PMP, Seahorse Bio-
sciences) in MAS-1 medium (Seahorse Biosciences) supplemented with 0.2% BSA (bovine se-
rum albumin). Complex IV activity was assayed as oxidation of its artificial electron donor 
N,N,N’,N’-tetramethyl-p-phenylene diamine (TMPD), as measured by the oxygen consumption 
rate. For these experiments, 105 MEFs per well (96-well plate) were seeded 24 h prior to the as-
say. ADP (4 mM) and succinate (10 mM) with rotenone (2 mM) were added to the medium to 
relieve respiratory control and place mitochondria in the metabolic state 3. Maximal activity of 
Complex IV was measured after inhibiting the upstream portion of the respiratory chain with 
Complex III inhibitor Antimycin A, followed by addition of TMPD (in the presence of ascorbic 
acid to keep it re-reduced). The specificity of the reaction was then verified using Complex IV 
inhibitor azide (20 mM). The mitochondrial membrane potential in MEFs was evaluated by 
TMRE staining and flow cytometry as described [42]. Respiration of intact Dox-induced cells in 
suspension was measured using a Clark-type electrode (Hansatech) as described [42]. Briefly, 
vector control or Opa11-289-expressing cells were resuspended in DMEM (10 million cells per 
ml) and basal (no additions), state 4 (oligomycin-induced) and state 3u (FCCP-induced) respira-
tion rates were measured in a ~20 min run. FCCP and oligomycin concentrations were 300 nM 
and 2 mg/ml, respectively.  
Statistical Analyses  
Unless noted otherwise, two-way analysis of variance (ANOVA) with post-hoc Bonferroni tests 
was performed using GraphPad Prism software.  Symbols: ***, P<0.001; **, P<0.01; *, P<0.05. 
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Figure Legends 
Figure 1. Opa1 protein level and mitochondrial morphology in MEFs isolated from the 
Opa1Q285STOP mouse. (A) Opa1 protein level is reduced in Opa1Q285STOP MEFs. Cytochrome c (Cyt 
c) is shown as a loading control. (B) Mitochondrial morphology in WT and Opa1Q285STOP MEFs. 
Scale bar 20 µm. (C) Representative images of different mitochondrial phenotypes: elongated, 
mixed (heterogeneous) and fragmented mitochondria. Scale bar 20 µm. (D) Quantification of the 
different phenotypes in WT and mutant MEFs. Data are means ± SEM from 6 independent cell 
cultures/plates combined from two independent preparations of MEFs.  
Figure 2. Delayed impairment in bioenergetic function and decreased expression of Complex IV 
in Opa1Q285STOP MEFs. (A, B) Assessment of the mitochondrial membrane potential by TMRE 
staining and flow cytometry: (A) A significant decline in mitochondrial membrane potential is 
observed in the Opa1 mutant MEFs (blue lines) at passage 6 but not at passage 2. Right panel 
shows the effect of FCCP (1 µM) that was used as a control for weak TMRE staining (low mem-
brane potential). (B) Quantification of the TMRE staining data. Data shown are percentage of 
cells with weak TMRE staining. Error bars are SD from 3-4 independent measurements. (C,D) 
Cellular respiration (Oxygen Consumption Rate, OCR) was measured in intact MEFs using Sea-
horse Biosciences Inc. technology. (C) Representative results obtained for WT and Opa1 mutant 
MEFs at different passages. Output panels of the Seahorse XF24 Flux Analyzer are shown, each 
representing “raw” data from an individual 24-well plate. Vertical lines indicate timing of injec-
tion of oligomycin (2 µg/ml) and sequential injections of FCCP (600 nM) to induce resting (State 
4) and maximal (State 3u) respiration, respectively. Data are means ±SE from 5-8 replicate 
wells. OCRs were significantly reduced in Opa1 mutant MEFs at passage 7 (left panel). Opa1 
null MEFs exhibited a nearly complete loss of respiration and were used as a positive control 
(right panel). (D) Summary of respiration measurements (7 experiments similar to one shown in 
C were performed and averaged). Basal (before additions), State 4 (resting, oligomycin-
inhibited) and State 3u (maximal FCCP-induced) OCR in WT and late passage (between 7 and 
10) mutant MEFs are shown. Data are means ± SE from 7 independent cell cultures/plates. (E) 
Western Blot analysis of ETC subunits in whole cell lysates prepared from WT and Opa1 mutant 
MEFs. Some blots also include samples from Opa1 null MEFs for comparison. The levels of 
Complex IV subunits (COX I and COX II) were reduced in Opa1 mutant MEFs while there were 
no decreases in the levels of Complex I subunits (ND4, NDUFB8, and NDUFS7). The levels of 
COX I subunit are shown on three immunoblots (from three independent cell lysate prepara-
tions). VDAC, Hsp60 or Tom20 remained unchanged in Opa1 mutant MEFs. The membranes 
from each individual blot were probed with an Opa1 antibody to verify the partial loss of Opa1 
in mutant samples. (See also Fig. S1). (F,G) Complex IV activity measured in MEFs permea-
bilized with perfringolysin O (PFO). (F) Results of a representative experiment shown as the 
Seahorse XFe96 Flux Analyzer output panel. Vertical lines indicate following injections: 1 µM 
Antimycin A (Ant A); 2.5 mM TMPD and 5 mM ascorbate (TMPD); 20 mM NaN3 (Azide). (G) 
Summary results of 3 experiments. Complex IV activity was measured as OCR in the presence 
of TMPD (as shown on panel F). Note that this reaction was almost completely inhibited by ad-
dition of NaN3 (“+ Azide”). Data are mean ± S.E.M. ***, ** and * denote statistically significant 
differences with P<0.001, P<0.01 and P<0.05, respectively.  
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Figure 3. Mutated Opa1 is not expressed at detectable levels in Opa1Q285STOP mice. (A) Samples 
of indicated tissues derived from the Opa1Q285STOP mice were probed for the presence of Opa11-285 
protein by Western Blot analysis using Opa1 antisera generated against an N-terminal Opa1 pol-
ypeptide. As a positive control for the specific antisera reactivity, samples of HeLa cells with 
doxycycline-inducible expression of Opa11-289 (also shown in panel C) or the recombinant Opa1 
polypeptide (rOpa1114-289) were loaded on the gels, where indicated. As a negative control for an-
tibody cross-reactivity, a sample of Opa1 null cells was added, where indicated. Samples were 
loaded at 30-50 µg per lane. Endogenous truncated Opa1 was not detected in any of the samples 
tested (including isolated liver mitochondria), while WT Opa1 and inducibly expressed Opa11-289 
were readily detected by the Opa1 antisera. (B) Quantification of Opa1 protein level confirms its 
~50% reduction in all mutant samples. (C) Doxycycline-induced Opa11-289 expression in HeLa 
cells one day (second lane) or 2 days (last lane) after the addition of doxycycline. Whole cell ly-
sates were loaded at 30 µg per lane. (D) Proteasomal inhibition by MG132 does not lead to ac-
cumulation of endogenous Opa11-285. MEFs were pretreated with 2 µM MG132 for 24 hours prior 
to cell lysate preparation. (Last 3 lanes on the blot contained the recombinant Opa1 polypeptide 
loaded at indicated amounts). The membrane was reprobed with ubiquitin antibody to confirm 
accumulation of ubiquinated proteins and VDAC antibody for a loading control. 
Figure 4. Differential effects of apoptogens on WT and Opa1Q285STOP MEFs. (A-D) Maximal res-
piratory capacity of intact cells (State 3u) treated with various apoptogens was determined in ex-
periments similar to one shown in Fig. 2 C. (A) 300 µM etoposide (Etop), 1 µM actinomycin D 
(Actin D), 1 µM thapsigargin (Thaps) and 2 µg/ml tunicamycin (Tunic) were added 24 h prior to 
the measurements, and STS (1 µM) was added for 5 hrs. All incubations were performed in the 
presence of 20 µM Q-VD.  . (B) Relative change in maximal respiratory capacity was calculated 
from data plotted in A. OCRs of apoptogen-treated WT and mutant MEFs were normalized to 
OCRs of respective untreated (either WT or mutant) cells in each experiment and averaged. Data 
shown are means ± SE, n=3-7. (C,D) Time course of the effect of ER stressors on respiration. 
WT and Opa1 mutant MEFs were treated with thapsigargin (C) or tunicamycin (D) for 1, 6 and 
24 h, and respective OCRs (averaged from 5 replicate wells for each time point) were normalized 
to untreated cells at time 0 h. (E) Representative images of WT and Opa1 mutant MEFs treated 
with indicated apoptogens (as in A) and immunostained for active Bax (red). Cells were also 
immunostained for Tim23 or cytochrome c (green) as indicated. Nuclei were stained with 
Hoechst 33342 (blue). Some confocal images are shown with phase-contrast to demonstrate cell 
morphology. Arrows indicate Bax-positive (apoptotic) cells. Scale bar 20 µm. Bax-positive cells 
were virtually absent from untreated samples. Panel F shows a fold change in the number of 
apoptotic Opa1 mutant cells relative to the WT. Statistical analysis was performed using one-
way ANOVA with post-hoc Newman-Keuls Multiple Comparison Test. Significant differences 
between effects of apoptogens are indicated (**, P<0.01).  Effects of apoptogens (STS, 
thapsigargin and tunicamycin) compared to control are also statistically significant (P<0.05). (G) 
Percentage of cells with activated Bax among WT and Opa1 mutant MEFs treated with 
thapsigargin, tunicamycin, or etoposide (as in A). Data are means ± SE from 3 independent ex-
periments. (For STS, the numbers were variable between experiments and only normalized data 
are shown in panel F).  
Figure 5. Expression of N-terminal Opa1 mutants has no effect on mitochondrial morphology 
and function. (A) Schematic representation of human Opa1 and the truncated mutants. Full-
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length wild-type Opa1 contains mitochondrial targeting sequence (MTS), a putative transmem-
brane domain (TM), two coiled-coil domains (CC), and a dynamin-like GTPase domain 
(GTPase). The truncated mutant (1-289) has only MTS, TM, and CC. (B,C) FLAG-tagged 
Opa11-289 mutant is localized to mitochondria. (B) Western blot of subcellular fractions shows 
localization of Opa11-289 (detected by FLAG antibody) in heavy membrane (M) fraction; VDAC 
was used as a marker for the membrane (mitochondria-enriched) fraction, and Bax and Drp1 
were the markers for the cytosolic (C) fraction. Samples were loaded at 30 µg per lane. (C) Con-
focal images showing mitochondrial localization of the FLAG-tagged Opa1 mutants (1-289, 1-
468, 1-194) and FLAG-tagged WT Opa1. Cells were immunostained with antibodies to FLAG 
(green) and Tom20 (red) to visualize mitochondrial morphology. Bottom panels also show a 
higher resolution image of mitochondria containing Opa11-289 (green). A zoomed-in area indicat-
ed by white rectangular in panel (a) is shown in panel b and its 3D reconstruction (isosurface 
rendering) is shown in panels c and d with translucent (c) and solidified (d) representation of the 
mitochondrial surface (red). Areas of colocalization are shown in yellow. See also Supplemen-
tary Fig. 2. (D) Quantification of mitochondrial phenotypes (tubular, fragmented or elongated) in 
cells overexpressing WT Opa1 or indicated Opa1 mutants. (E) Cellular respiration (OCR) was 
measured in intact control cells (vector) and cells expressing Opa11-289: basal (before additions), 
State 4 (resting, oligomycin-inhibited) and State 3u (maximal FCCP-induced) OCR. Data are 
means ± SD from 3 independent cell cultures. 
Figure 6. Opa11-289 mutant decreases Bax activation in etoposide-treated cells. (A) Dox-induced 
expression of FLAG-tagged Opa11-289 coupled with the expression of GFP (Opa11-289-IRES-GFP 
cells). Cells were fixed and immunostained with FLAG and Tom20 antibodies (upper panels) or 
the N-terminal Opa1 antibody (bottom panels). A representative image shows GFP-positive 
Opa11-289-expressing cells (green), which display FLAG staining (blue) overlapping with Tom20 
staining (red) yielding pink color. Neighboring non-expressing cells (GFP-negative) display only 
Tom20 staining (red). Bottom panels show representative cells with modest (~2 fold) expression 
levels of Opa1 1-289.  Scale bar 20 µm. (B) Representative images of etoposide-treated Opa11-289, 
Opa11-194 and vector control cells (two fields are shown for each cell type as indicated). Expres-
sion of the indicated Opa1 mutants was coupled with the expression of GFP (as in A). Cells were 
fixed and immunostained with FLAG (blue) and Bax(N20) (red) antibodies after 24 h treatment 
with 300 µM etoposide in the presence of 20 µM Q-VD. Arrows show examples of GFP-positive 
cells that have not undergone apoptosis and do not show Bax activation. Scale bar 20 µm. (D) 
Quantification of Bax activation among GFP-positive cells and GFP-negative cells (as an inter-
nal control). Data are mean ± SEM from 4 – 6 independent experiments.  
Supplementary Figure 1. A. Mitochondrial respiration (OCR) measured in WT and 
Opa1Q285STOP MEFs permeabilized with perfringolysin O (PFO). State 3 respiration was induced 
by addition of 4 mM ADP. State 4 (oligomycin-inhibited) and State 3u (FCCP-induced) OCR 
were measured as described in Fig. 2C for intact cells. Data shown are mean ± SE from 3 exper-
iments. B. Complex IV level was reduced in Opa1Q285STOP MEFs. Western Blot analysis of Com-
plex IV subunits (Cox I and COX II) in whole cell lysates prepared from independent cultures of 
WT and Opa1 mutant MEFs. Hsp60 is shown as a loading control. The blot on the right (dis-
played at two exposure times) also includes a sample from Opa1 null MEFs for comparison.  
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Supplementary Figure 2. Analysis of mitochondrial localization of Opa11-289 mutant (Opa1-
FLAG) by superresolution microscopy. Doxycycline-induced cells expressing Opa11-289 were 
immunostained with FLAG and either Tim23 or Tom20 antibodies as indicated. Uninduced 
(non-expressing) cells were stained with Opa1 and Tim23 antibodies (upper panels) for compara-
tive analysis of endogenous WT Opa1. Bottom panels also show Tim23 vs. Tom 20 analysis. 
Opa1 localization relative to the inner membrane (Tim23) or the outer membrane (Tom20) mark-
ers is shown as a color-based distance map (green-red – less than 140nm; blue-purple - greater 
than 140nm) depicted in each panel. Numbers indicate the percentage +/-SEM of the total num-
ber of objects per cell within the shortest distance between objects (color coded green-red - less 
than 140nm). An average of 3 cells per group was analyzed. 
Supplementary Figure 3. Effects of apoptogens on the level of WT and mutant Opa1. Western 
blot analysis of whole cell lysates prepared from Dox-induced cells expressing either FLAG-
tagged Opa11-289 or FLAG-tagged Opa11-469 and treated with 300 µM etoposide or 10 µM actino-
mycin D (Act D) in the presence of 20 µM Q-VD for indicated time (h). Both apoptogens induce 
variable degrees of degradation of endogenous Opa1 and Opa1 mutants. The levels of Opa1 mu-
tants are also shown at a higher exposure time (bottom panel). Opa1 mutants were detected with 
FLAG antibody. Hsp60 is shown as a loading control. 
	  
 
 
 









